Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Another Positive mention of Genedrive , seems like Genedrive stepped up the PR .
In the UK, minnow Genedrive has developed rapid molecular point of care tests to detect coronavirus and hepatitis C as well as one to identify newborn babies susceptible to deafness when given the drug gentamycin.
Earlier this year, the firm also sealed a partnership with US diagnostics and life sciences group Beckman Coulter to distribute the genedrive PCR COVID-19 lab test in the US and Europe.
Underscoring the growing interest in the area, in recent days a consortium involving Bill Gates and George Soros announced it was acquiring UK testing company Mologic as part of a push to make tests more widely available to diagnose tropical diseases in developing countries.
https://capital.com/healthy-opportunity
https://ca.finance.yahoo.com/news/divoc-health-empowers-10-000-122527908.html
Just this update for bow.
https://www.linkedin.com/posts/genedrive-plc_ias-2021-ias-conference-on-hiv-science-activity-6822855237167026176-Kuq-
Here is the content if u don’t have premium.
NEW YORK — Even as it has its eye on launching a test for SARS-CoV-2, Genedrive is circling back to its legacy business.
Genedrive aims to have a point-of-care molecular test for SARS-CoV-2 on the European clinical market within the next few months, according to its CEO David Budd. And while the COVID-19 pandemic has drawn its attention, as it has done for most firms in the molecular diagnostics space, Genedrive is renewing its focus on other tests in its menu, he added.
The Manchester, UK-based company had previously planned to have a CE-IVD marked point-of-care SARS-CoV-2 test out by June 30, but informed shareholders earlier this month that it would miss that deadline, citing a "longer than anticipated development time."
"Since we missed the deadline, we had to update the market on our progress," Budd remarked. "It was a line we had previously drawn in the sand."
In its statement, Genedrive noted "significant technical hurdles" in the test's development, as well as its desire to improve the performance specifications of the platform, as the requirements of the SARS-CoV-2 testing market have been evolving, especially related to sensitivity, specificity, speed, ease of use, and scalability.
"In developing these things, half of it is biological, so it's not like building a house where you can buy some timber, screws, and assemble it," commented Budd. "Stuff happens that you don't always have control over, but we managed to do away with a lot of the uncertainty upfront," he said. Budd also noted that there have been scientific advances related to direct PCR that have allowed the company to improve its workflow as it prepares the product for a CE-IVD mark.
Genedrive's test relies on a nasopharyngeal swab as a sample source, and Budd said that Genedrive developed a proprietary lysis buffer to deliver biosafety to the product both before and after the swab is used. Public Health England is currently assessing the biosafety of the method.
The firm's handheld eponymous instrument includes a PCR thermocycling device that provides rapid nucleic acid amplification and detection results and allows users to detect SARS-CoV-2-positive samples in about 10 minutes, with negatives reported after 20 minutes if no signal is detected. The system fits in a user's palm, is 12 cm by 18 cm by 10 cm, and weighs 600 grams, Budd said. The list price for the system is less than $3,000 and normally offered as part of a reagent rental package, he added.
The test targets two genes in the SARS-CoV-2 genome, and is inclusive of all variants of concern, including the delta variant. An internal validation study found 100 percent concordance with 30 positive and 30 negative samples tested originally with real-time PCR.
The four-step workflow relies on an eye dropper liquid transfer process so that non-technicians can run the test. The company is currently targeting a late September or early October date fo
This is what I heard from BC guy about takeover .
“I have no idea and strategically Beckamn is with danaher and they have IDT and Cepheid for primers and kits, personally I don’t think it will happen”
I have emailed him on Monday but didn’t get any reply , i am happy with the GDR products and prospect , but I am concerned with Mr Budd’s attitude and arrogance , we shareholders don’t deserve to be treated like this , absolutely zero communication when the shares price lost 200% but he comes out to announce bad when the sp catching up . If he would like to protect the investors then the it should be both ways . Hope he does something to save the SP. good luck
According to this , Genedrive has 12 million dollar contract with DOD and Genedrive supplied 2.2 mil worth goods so far .
https://govtribe.com/vendors/epistem-limited-kcy55
Below DOD doc talks About Genedrive , published 2 days ago.
https://comptroller.defense.gov/Portals/45/Documents/defbudget/fy2022/budget_justification/pdfs/02_Procurement/ROC_Vol1_DW_PROC_PB22_Justification_Book_Final.pdf
“ Remarks: The Joint Handheld Bio-Agent Identifier (JHBI) program is a Joint Service Acquisition Category (ACAT) III program that addresses an existing United States Special Operations Command (SOCOM) requirement for handheld, multiplexed, environmental, bio-agent identification. The JHBI program will provide handheld bio-collection preparation, and identification systems for the rapid and accurate identification of organisms at the point of contact for multiple mission types. Biomeme developed the "two3" system for Increment 1 and is improving that system to become the "three9" system for Increment 2. Both are highly multiplexed, smart phone-based, Polymerase Chain Reaction (PCR) identification systems. Epistem is developing the "Genedrive", a 9-plex PCR system. The proposed JHBI systems will be handheld, PCR-based, multiplexed devices for the analysis of powder or liquid environmental biological samples and will be supported by tools for quickly collecting and preparing raw biological samples for use on these identifiers. JHBI capabilities will provide Special Operations Forces with timely and accurate identification of eight or more bio-agents at the point of need. Additional capabilities will be developed to meet timephases or objective requirements. These capabilities may include additional chemical, biological, radiological, and nuclear (CBRN) threat assays, integrated sample preparation capabilities, and supporting capabilities, as required. In FY22, the program will provide handheld bio-identification systems for the rapid and accurate identification of organisms at the point of contact for multiple mission types to CBRN DRS System (DR-SKO) Enhancement Package 1 and Joint Biological Tactical Detection System (JBTDS). Justification: In FY22 JHBI will procure the Genedrive for DR-SKO (NGB 57, USAF 85) and the Three-9 for JBTDS (NGB 19, USMC 25). FY22 will also fund fielding and program management support.“
@Preefty, I have managed to speak with Dr Kahol in Dec 2020, they will be taking all Genedrive products to India and his aim is to setup around 100 labs across India by end 2022 , he has got the financials backup from LionsHead.